Yahoo Finance EN

Collegium Pharmaceutical touts record 2025, sees JORNAY PM driving 2026 growth at Barclays Miami Conference

Mar 14, 2026 &03021414202631; 18:02 UTC finance.yahoo.com Trending 3/5

Read original on finance.yahoo.com ↗

↗

Positive for markets

Sentiment score: +75/100

Moderate impact Medium-term (weeks)

WHAT THIS MEANS

Collegium Pharmaceutical reported record 2025 results and projects continued growth in 2026, with JORNAY PM expected to be a key revenue driver. The company's positive outlook suggests strong market demand for its ADHD medication portfolio.

AI CONFIDENCE

0% Low

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↑

COLL

COLLStock

Expected to rise

Record 2025 results and positive 2026 guidance with JORNAY PM as growth catalyst

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Consider accumulating COLL on any pullbacks given strong fundamentals and clear growth catalysts. Monitor JORNAY PM commercial execution and market adoption rates as key performance indicators for 2026 thesis validation.

KEY SIGNALS

Record 2025 financial performanceJORNAY PM identified as primary 2026 growth driverPositive management guidance at investor conferenceADHD medication market strengthProduct pipeline momentum

SECTORS INVOLVED

HealthcarePharmaceuticalsSpecialty Pharma

Analysis generated on Mar 16, 2026 at 12:17 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Yahoo Finance. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Collegium Pharmaceutical touts record 2025, sees JORNAY PM driving 2026 growth at Barclays Miami Conference

RELATED INTELLIGENCE